### **Supplementary Data**

Supplementary Figure 1, Supplementary Table 1, Supplementary Table 2

# Bivalent COVID-19 vaccine antibody responses to Omicron variants suggest that responses to divergent variants would be improved with matched vaccine antigens

Wei Wang<sup>1</sup>, Emilie Goguet<sup>2</sup>, Stephanie Paz Padilla<sup>1</sup>, Russell Vassell<sup>1</sup>, Simon Pollett<sup>3,4</sup>, Edward Mitre<sup>2\*</sup>, Carol D. Weiss<sup>1\*</sup>


#### Affiliations

<sup>1</sup>Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA

<sup>2</sup>Department of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, USA

<sup>3</sup>Infectious Diseases Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA

<sup>4</sup>Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, United States of America Supplementary Figure 1



Supplementary Figure 1. Strobe chart of the study cohort. Details of the Prospective Assessment of SARS-CoV-2 Seroconversion (PASS) study protocol, including details of the inclusion/exclusion criteria, have been published (Jackson-Thompson BM, Goguet E, Laing ED, et al. Prospective Assessment of SARS-CoV-2 Seroconversion (PASS) study: an observational cohort study of SARS-CoV-2 infection and vaccination in healthcare workers. BMC Infect Dis. Jun 9 2021;21(1):544. doi:10.1186/s12879-021-06233-1). The PASS (Protocol IDCRP-126) studies were approved by the Uniformed Services University of the Health Sciences Institutional Review Board in compliance with all applicable federal regulations governing the protection of human participants. All study participants provided informed consent. Inclusion criteria included being generally healthy,  $\geq 18$  years old, and employed at the Walter Reed National Military Medical Center. Exclusion criteria included history of COVID-19, IgG seropositivity for SARS-CoV-2, and being severely immunocompromised at time of screening. The study was initiated in August 2020, with rolling enrollment through February of 2021. Serum samples for antibody testing were collected monthly through August of 2021, then quarterly through August of 2022, and then semiannually after that. Participants are asked to test for SARS-CoV-2 infection any time they have symptoms. Details of SARS-CoV-2 infections and vaccinations are collected at every study visit. A total of 271 individuals were enrolled, with 148 still being actively followed as of January 2023. The subset of participants included in this study were those who had four or five documented antigen exposures (sum of vaccine doses and SARS-CoV-2 infections) and had serum available between one and 12 weeks after the most recent antigen exposure. A total of 63 participants were included in this study, and a total of 68 serum samples were analyzed as five of the participants had serum available after both four and five antigen exposures. N: number of participants.

2

	Overall			V2 + DV1				
Characteristics	population	V4 (N=16)	V3+Bi (N=18)	V3+PVI	V4+Bi (N=9)			
	(N=63)			(N=25)				
Sex								
Female	42 (66.7%)	10 (62.5%)	10 (55.6%)	18 (72.0%)	7 (77.8%)			
Male	21 (33.3%)	6 (37.5%)	8 (44.4%)	7 (28.0%)	2 (22.2%)			
Age								
18-44	29 (46.0%)	2 (12.5%)	14 (77.8%)	12 (48.0%)	1 (11.1%)			
45-64	32 (50.8%)	13 (81.3%)	4 (22.2%)	13 (52.0%)	7 (77.8%)			
65+	2 (3.2%)	1 (6.2%)	0 (0%)	0 (0%)	1 (11.1%)			
Median age (IQR)	46 (16)	55.5 (7)	39.5 (7.75)	45 (15)	54 (6)			
Charlson Co-morbidi	ity Index							
0	53 (84.1%)	13 (81.3%)	16 (88.9%)	21 (84.0%)	6 (66.7%)			
1	7 (11.1%)	1 (6.2%)	2 (11.1%)	3 (12.0%)	1 (11.1%)			
2	2 (3.2%)	1 (6.2%)	0 (0%)	1 (4.0%)	1 (11.1%)			
3	1 (1.6%)	1 (6.2%)	0 (0%)	0 (0%)	1 (11.1%)			
Length of time (days) between serum collection and most recent antigen exposure								
Median days (IQR)	35 (29)	33 (30.5)	29 (7)	56 (38)	35 (14)			

#### Supplementary Table 1. Characteristics of clinical cohort.

Sixty-three participants were included in this study and a total of 68 serum samples were collected and distributed into four antigen exposure groups: V3+Bi (3 ancestral mRNA and 1 bivalent mRNA vaccines), V3+PVI (3 ancestral mRNA vaccines followed by a post-vaccination infection during BA.1 wave), V4 (4 ancestral mRNA vaccines), and V4+Bi (4 ancestral mRNA and 1 bivalent mRNA vaccines. Serum was collected at two different antigen exposure time-

points for five participants who contributed to the V4 and V4+Bi groups. IQR, Interquartile range.

ID	Participant status at time of collection	Time between last vax and collection (days)	Time between infection and collection (days)	D614G	BQ.1.1	BA.4/5	XBB	XBB.1.5
01	V4	7		14471	2314	375	133	174
02	V4	51		8322	589	186	199	217
03	V4	10		13786	1613	279	157	233
04	V4	27		24577	7071	1477	606	1100
05	V4	23		12634	376	87	92	98
06	V4	21		15268	1365	218	164	191
07	V4	40		4841	189	73	53	<40
08	V4	56		9989	1663	227	48	62
09	V4	14		9930	987	442	230	274
10	V4	52		9138	1177	198	85	103
11	V4	32		10273	2536	1268	781	402
12	V4	25		5593	664	258	44	<40
13	V4	67		6313	604	166	196	222
14	V4	57		7661	470	174	71	70
15	V4	34		25657	3916	867	392	577
16	V4	73		24528	632	262	304	403
17	V3+Bi	35		9927	2207	1356	530	451
18	V3+Bi	18		2180	153	59	<40	<40
19	V3+Bi	28		23643	3447	1123	440	1181
20	V3+Bi	28		6752	2060	209	116	115

## Supplementary Table 2. Neutralization titers

21	V3+Bi	27		12846	2312	1345	445	592
22	V3+Bi	29		51977	6948	1735	311	542
23	V3+Bi	8		10807	1267	154	115	144
24	V3+Bi	27		20919	2412	1277	639	502
25	V3+Bi	42		70398	17467	3364	2226	2980
26	V3+Bi	33		45749	5806	939	392	507
27	V3+Bi	39		15990	6573	1194	669	1010
28	V3+Bi	35		8213	1985	308	114	108
29	V3+Bi	65		6775	1098	191	200	333
30	V3+Bi	29		16935	10600	1517	861	998
31	V3+Bi	28		4799	1230	184	83	129
32	V3+Bi	33		1890	163	48	56	70
33	V3+Bi	28		15191	2854	779	765	1077
34	V3+Bi	54		12858	1532	1253	324	391
35	V3+PVI	264	91	31776	8335	614	350	411
36	V3+PVI	123	7	6567	189	<40	<40	44
37	V3+PVI	286	63	11339	2361	469	294	373
38	V3+PVI	120	27	26460	2822	652	1026	712
39	V3+PVI	139	37	48306	8362	1484	618	1225
40	V3+PVI	123	42	11954	1238	334	152	201
41	V3+PVI	169	71	16645	2259	561	481	371
42	V3+PVI	267	40	21525	2830	732	324	495
43	V3+PVI	182	79	12641	1694	243	94	131
44	V3+PVI	177	99	5087	714	128	95	91
45	V3+PVI	328	93	15099	5907	1510	516	614
46	V3+PVI	167	80	16113	3529	137	99	154
47	V3+PVI	242	29	9934	511	148	71	89
48	V3+PVI	167	83	14151	2737	332	283	287

49	V3+PVI	125	39	11190	881	97	71	85
50	V3+PVI	148	70	16742	1665	368	271	335
51	V3+PVI	160	70	16188	5048	747	418	662
52	V3+PVI	150	52	5833	796	64	84	94
53	V3+PVI	383	30	6796	3905	494	157	178
54	V3+PVI	169	22	1136	159	91	56	59
55	V3+PVI	284	62	18961	4144	776	382	847
56	V3+PVI	289	37	11027	2274	865	532	668
57	V3+PVI	245	23	7079	1041	157	115	174
58	V3+PVI	390	56	51643	17884	1538	595	1111
59	V3+PVI	138	75	19321	7278	542	149	245
60	V4+Bi	39		1701	162	98	<40	<40
61	V4+Bi	43		10494	1700	328	214	347
62	V4+Bi	29		15316	2298	503	231	309
63	V4+Bi	35		41391	18221	5163	1551	1320
64	V4+Bi	34		8988	1455	309	162	117
65	V4+Bi	27		3133	155	63	<40	<40
66	V4+Bi	55		9799	4039	2279	975	683
67	V4+Bi	20		9427	3448	1076	409	669
68	V4+Bi	43		6959	687	193	79	134